The CANTOS Trial
Authors:
- Richard A. BaylisRBRichard A. Baylis
- Delphine GomezDelphine Gomez
- Ziad MallatZiad Mallat
- Gerard PasterkampGPGerard Pasterkamp
- Gary K. OwensGary K. Owens
- 1 November 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 37 (11) , e174-e177
Abstract
The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.Keywords
This publication has 26 references indexed in Scilit:
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in miceScience, 2017
- How Common Is Residual Inflammatory Risk?Circulation Research, 2017
- Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial InfarctionCirculation, 2015
- The IL-1 Pathway in Type 2 Diabetes and Cardiovascular ComplicationsTrends in Endocrinology & Metabolism, 2015
- KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesisNature Medicine, 2015
- Macrophages in atherosclerosis: a dynamic balanceNature Reviews Immunology, 2013
- Inflammation in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Macrophage death and defective inflammation resolution in atherosclerosisNature Reviews Immunology, 2009